Reduction of blood transfusions in cold agglutinin disease

Reduction of blood transfusions in cold agglutinin disease addresses severe, chronic anemia in patients affected by this rare autoimmune hemolytic disorder This therapeutic indication targets the mitigation of ongoing erythrocyte destruction to lessen supportive red blood cell transfusion requirements, alleviate profound fatigue, and reduce risks of transfusion-associated complications

Reduction of blood transfusions in cold agglutinin disease addresses severe, chronic anemia in patients affected by this rare autoimmune hemolytic disorder

Cold agglutinin disease primarily involves the hematologic and immune systems, characterized by low-grade clonal B-cell proliferation that produces cold-reactive immunoglobulin M autoantibodies

Cold agglutinin disease primarily involves the hematologic and immune systems, characterized by low-grade clonal B-cell proliferation that produces cold-reactive immunoglobulin M autoantibodies At lower temperatures in peripheral circulation, these autoantibodies bind erythrocyte surface antigens and trigger classical complement pathway activation, resulting in predominantly C3b-mediated extravascular hemolysis in the liver and subsequent transfusion dependence This therapeutic indication target...

At lower temperatures in peripheral circulation, these autoantibodies bind erythrocyte surface antigens and trigger classical complement pathway activation, resulting in predominantly C3b-mediated extravascular hemolysis in the liver and subsequent transfusion dependence